Skip to main content
Contact Us
Subscribe
E-Edition
52°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by KalVista Pharmaceuticals, Inc.
< Previous
1
2
3
4
Next >
KalVista Pharmaceuticals to Present Data at the 2023 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology
November 02, 2023
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALV
KalVista Pharmaceuticals Presents Data on HAE Attacks in Patients Receiving Long-Term Prophylaxis at the Asia Pacific Association of Allergy, Asthma and Clinical Immunology 2023 International Conference
October 24, 2023
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALV
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 03, 2023
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALV
KalVista Pharmaceuticals to Present at Cantor Global Healthcare Conference
September 19, 2023
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALV
KalVista Pharmaceuticals Reports First Fiscal Quarter Results and Provides Operational Update
September 07, 2023
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALV
KalVista Pharmaceuticals to Present HAE Attack Journey Data at 2023 HAEi Regional Conference EMEA
August 28, 2023
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALV
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 02, 2023
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALV
KalVista Pharmaceuticals Expands Senior Leadership Team with Appointment of Nicole Sweeny as Chief Commercial Officer
July 25, 2023
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALV
KalVista Pharmaceuticals Presents New HAE Attack Journey Data at 2023 US HAEA National Summit
July 24, 2023
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALV
KalVista Pharmaceuticals Provides Operational Update and Fiscal Year Financial Results
July 07, 2023
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALV
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 05, 2023
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALV
KalVista Pharmaceuticals Presents New Data at 2023 Meeting of the European Academy of Allergy and Clinical Immunology
June 12, 2023
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALV
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 05, 2023
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALV
KalVista Pharmaceuticals to Present Data at the 2023 Meeting of the European Academy of Allergy and Clinical Immunology (EAACI)
June 02, 2023
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALV
KalVista Pharmaceuticals to Present at Jefferies Global Healthcare Conference
May 31, 2023
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALV
KalVista Pharmaceuticals to Present at Stifel 2023 Tailoring Genes: Genetic Medicines Day Virtual Conference
May 23, 2023
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALV
KalVista Pharmaceuticals Presents Data at 13th C1-inhibitor Deficiency & Angioedema Workshop
May 08, 2023
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALV
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 02, 2023
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALV
KalVista Pharmaceuticals to Present Data at the 13th C1-inhibitor Deficiency & Angioedema Workshop
April 27, 2023
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALV
KalVista Pharmaceuticals to Present at 22nd Annual Needham Virtual Healthcare Conference
April 12, 2023
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALV
KalVista Pharmaceuticals Reports Third Fiscal Quarter Results
March 09, 2023
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALV
KalVista Pharmaceuticals Presents Data at American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting
February 27, 2023
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALV
KalVista Pharmaceuticals to Present Data at the 2023 American Academy of Allergy, Asthma & Immunology
February 16, 2023
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALV
KalVista Pharmaceuticals Provides Progress Updates on Sebetralstat Development
February 14, 2023
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALV
KalVista Pharmaceuticals Announces Publication of Sebetralstat Phase 2 Data in The Lancet
February 10, 2023
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALV
KalVista Pharmaceuticals Presents Data at Western Society of Allergy, Asthma & Immunology (WSAAI) 60th Annual Scientific Session
February 07, 2023
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALV
KalVista Pharmaceuticals to Present at SVB Securities Global Biopharma Conference
February 03, 2023
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALV
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 02, 2023
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALV
KalVista Pharmaceuticals Announces Benjamin L. Palleiko Promoted to President
January 05, 2023
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALV
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 04, 2023
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALV
< Previous
1
2
3
4
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.